(Q41612183)

English

A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers

scientific article published on October 2000

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers (English)

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

M Bani

1

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

A Colantoni

2

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

M Guillaume

3

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

F Macchi

4

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

G Moroni

5

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

S Persiani

6

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

language of work or name

0 references

publication date

1 October 2000

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

British Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

50

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

4

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

338-349

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

Emerging treatments for hypertension: potential role for vasopeptidase inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014992

6 June 2018

Recent advances in antihypertensive therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014992

6 June 2018

The renin system and new understanding of the complications of hypertension and their treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014992

6 June 2018

RHC 3659: a new orally active angiotensin converting enzyme inhibitor in normal volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014992

6 June 2018

Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014992

6 June 2018

Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014992

6 June 2018

Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014992

6 June 2018

Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014992

6 June 2018

Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014992

19 August 2018

Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014992

19 August 2018

Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014992

19 August 2018

Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014992

2 December 2018

Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11012557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/11012557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for edematous disorders and hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/11012557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/11012557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II

1 reference

https://pubmed.ncbi.nlm.nih.gov/11012557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Systemic and regional hemodynamic effects of a new angiotensin converting enzyme and neutral endopeptidase mixed inhibitor, alatriopril, in the dog]

1 reference

https://pubmed.ncbi.nlm.nih.gov/11012557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/11012557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/11012557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/11012557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/11012557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11012557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/11012557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/11012557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/11012557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1046/J.1365-2125.2000.00257.X

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

5 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41612183&oldid=2144211952"